Deal of the Day — limited-time pharmacy picks!
Hepcdac 60mg Tablet

Hepcdac 60mg Tablet

Prescription requiredRx Required

Salt Composition: Daclatasvir 60 mg

Expiry Date: 01/2028

Special offer

Buy at $92.53

$92.53

Inclusive of all taxes

▼

28 Tablet in Bottle

About The Product

Hepatitis C

  • The Hepcdac 60mg tablets fall under a class of antiviral drugs, which are used in conjunction with other drugs such as sofosbuvir in order to treat chronic hepatitis C infection in adult patients.
  • As inhibitors of the nonstructural protein 5A (NS5A), the medication is instrumental in suppressing the replication of the virus, causing it to be eliminated from the body, consequently reducing the likelihood of developing liver complications, including cirrhosis and liver cancer.
  • These medications may be taken in combination therapy for the indicated duration, between 12 and 24 weeks as specified by the physician.
  • They may be taken either before or after eating, but the patient should not discontinue use without first talking to their healthcare provider.
  • Some of the possible side effects include headaches, drowsiness, fatigue, anemia, and nausea. The medication is contraindicated in pregnant women and children below 18 years of age.

Side Effects

Hepcdac 60mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

  • Nausea
  • Headache
  • Fatigue / tiredness
  • Dizziness
  • Insomnia (difficulty sleeping)
  • Anemia (low red blood cell count)
  • Decreased heart rate
  • Liver failure
  • Reactivation of hepatitis B virus

How To Use

  • The doctor determines the dosage of Hepcdac 60mg Tablet as per the patient's health and other medical conditions.
  • Take this medicine at the same time every day as prescribed by your doctor for effective results.
  • It can be taken orally, with or without food. In case of an overdose, contact your doctor immediately.

Safety Advice

Alcohol
There is no information regarding the safety of alcohol consumption while on Daclatasvir. Please consult your doctor for further details.
Pregnancy
The use of Hepcdac 60mg Tablet is not advised for pregnant women due to some evidence that it might pose a risk to the fetus. But it can still be used in cases where its benefits outweigh its risks.
Breast Feeding
Hepcdac 60mg Tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Driving
Hepcdac 60mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
Consumption of Hepcdac 60mg Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
Consumption of Hepcdac 60mg Tablet should be avoided without informing the doctor if you have any liver-related issues.

Missed Doses

  • If you miss a dose of Hepcdac 60 mg tablet, make sure to consult your healthcare provider.
  • Take it as soon as possible. Do not double the dose to catch up.

FAQs

Hepcdac 60 mg is an antiviral medication, which is used with other medications in the treatment of chronic Hepatitis C Virus (HCV) infection in adults.

References

  • Herbst, D. A., & Reddy, K. R. (2013). NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert opinion on investigational drugs, 22(10), 1337-1346 - https://pubmed.ncbi.nlm.nih.gov/23931586/
  • Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., ... & Grasela, D. M. (2014). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine, 370(3), 211-221 -  https://pubmed.ncbi.nlm.nih.gov/24428467/
  • Vyas, B. H., Darji, N. H., Rana, D. A., Vyas, K. Y., & Malhotra, S. D. (2021). Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients. Perspectives in Clinical Research, 12(2), 76-82.
  • Elliott, W. T. (2015). Daclatasvir Tablets (Daklinza). Internal Medicine Alert, 37(21).
  • Pellicelli, A. M., Montalbano, M., Lionetti, R., Durand, C., Ferenci, P., D’Offizi, G., ... & Angelico, M. (2014). Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease, 46(10), 923-927 - https://pubmed.ncbi.nlm.nih.gov/24997638/

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026